Before revision: It is the first, and hitherto novel, apheresis technology with a demonstrated efficacy in targeting and removing selected leukocytes while leaving all other blood cells unaffected.Clinical Immunology Volume 149, Issue 1, October 2013, Pages 73–82 The immunotherapy has been evaluated in a Phase I/II placebo-controlled clinical trial, where all primary and secondary clinical endpoints were successfully met and the treatment showed complete absence of any side effects of clinical significance.ClinicalTrials.Gov 2010 This represents an important progress beyond the state-of-the-art in anti-inflammatory therapeutics since TLA can dampen inflammation without blocking systemic inflammatory pathways or causing a general immunosuppression, which are characteristic of existing treatment.
After revision: It is the first, and hitherto novel, apheresis technology with a demonstrated efficacy in targeting and removing selected leukocytes while leaving all other blood cells unaffected.Clinical Immunology Volume 149, Issue 1, October 2013, Pages 73–82 The immunotherapy has been evaluated in a Phase I/II placebo-controlled clinical trial, where all primary and secondary clinical endpoints were successfully met and the treatment showed an absence of any side effects of clinical significance.ClinicalTrials.Gov 2010